Beam Therapeutics Inc.BEAM

Healthcare
Neutral

ASignal's systematic analysis rates BEAM as Neutral. Beam Therapeutics Inc. has a market cap of $3.90B, a -40.2% net margin, and 324.9% year-over-year revenue growth.

Reflects the latest available analysis · analyzed Jul 7, 2026

The case on BEAM

Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.

Bull case
  • Strong revenue growth (324.9% YoY)
  • High cash position ($1.21B total cash)
  • Low debt-to-equity ratio (0.22x)
  • Current ratio extremely high (16.99x)
  • MACD above signal line with expanding histogram
  • Price above 20-day and 50-day moving averages
VS
Bear case
  • Negative profit, operating, and gross margins
  • Negative EV/EBITDA (-7.32x) and forward P/E (-8.02x)
  • Free cash flow deeply negative (-$233.56M)
  • RSI at 73.19 — overbought condition
  • Price at upper Bollinger Band — potential reversal risk
  • No Reddit mentions — low retail sentiment visibility

Key facts

Sector
Healthcare
Market cap
$3.90B
Gross margin
-146.9%
Net margin
-40.2%
Rev growth YoY
324.9%
Price (Jul 7, 2026)
$37.92
Subscriber-only

See the full verdict on BEAM

ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.

How ASignal analyzes BEAM

Most investors never get a second opinion, let alone several. ASignal runs BEAM past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.

The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.

Beam Therapeutics Inc. (BEAM) Stock Analysis - ASignal rates it Neutral